Antibodies | The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease

This study systematically evaluates the value of anti-MCV antibodies as a potential biomarker for RA-ILD, highlighting their potential application in risk stratification and early screening, thereby providing a reference for experimental design in serological marker research for autoimmune lung diseases.

 

Literature Overview

The article "The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review", published in the journal 'Antibodies', systematically investigates the diagnostic performance and clinical associations of anti-mutated citrullinated vimentin (anti-MCV) antibodies in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Through structured literature retrieval and evidence mapping, the study reveals a significant elevation of anti-MCV in patients with pulmonary involvement, suggesting its potential role as an auxiliary biomarker in disease phenotype stratification.

Background Knowledge

Rheumatoid arthritis (RA) is a systemic autoimmune disorder, and interstitial lung disease (ILD) is a leading cause of mortality, particularly associated with poorer prognosis in male and elderly patients. Currently, early detection of RA-ILD remains challenging due to nonspecific symptoms often mistaken for aging or comorbidities. Although high-resolution CT (HRCT) and pulmonary function tests (PFTs) are diagnostic gold standards, radiation exposure and cost limit their widespread use for screening. Therefore, there is an urgent need for reliable serum biomarkers to enable risk stratification and early intervention. Current research focuses on the anti-citrullinated protein antibody (ACPA) family, among which anti-CCP antibodies are widely used but show limited specificity for RA-ILD. In contrast, anti-MCV is a more pathobiologically plausible candidate biomarker because its target antigen, vimentin, is highly expressed in lung interstitial cells and fibroblasts. However, the lack of standardization in detection platforms and cutoff values leads to high heterogeneity across studies, limiting clinical translation. This study aims to systematically synthesize existing evidence to evaluate the independent diagnostic value and phenotypic associations of anti-MCV in RA-ILD, providing direction for future standardized research.

 

 

Research Methods and Experiments

The authors employed a scoping review methodology, following the PRISMA-ScR guidelines, to search four major databases—PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library—for original studies assessing the role of anti-MCV antibodies in RA-ILD. Only two observational studies met the inclusion criteria: a cross-sectional study (Tian et al., 2016) and a case-control study (Elsayed et al., 2024). The research extracted data on population characteristics, detection methods, positivity thresholds, and primary outcome measures. Descriptive synthesis was used for data analysis, focusing on comparing anti-MCV positivity rates and titers between RA-ILD patients and RA patients without pulmonary involvement, and assessing correlations with disease activity and pulmonary function parameters.

Key Conclusions and Perspectives

• Both studies found significantly higher anti-MCV antibody positivity rates and serum titers in RA-ILD patients compared to RA patients without pulmonary involvement, indicating a strong association with lung involvement.
• The study by Tian et al. showed that anti-MCV was independently associated with RA-ILD, whereas anti-CCP levels showed no significant difference, suggesting that anti-MCV may provide additional diagnostic information and guiding significance for subsequent serotyping studies.
• The study by Elsayed et al. further found that anti-MCV titers were negatively correlated with DLCO and FVC, indicating that anti-MCV levels correlate with the degree of pulmonary functional impairment, offering guidance for future pulmonary function prediction models.
• The two studies used different ELISA platforms (ORGENTEC vs. CUSABIO) and different positivity thresholds (≥20 U/mL vs. >20 U/mL), and the optimal cutoff values derived from ROC curves (155.5 U/mL) were significantly higher than conventional thresholds, highlighting the necessity of test standardization and providing guidance for future multicenter validation studies.

Research Significance and Prospects

This study reveals the potential of anti-MCV as a biomarker for RA-ILD, supporting its application in disease phenotype stratification. Future studies should validate its predictive value in larger cohorts and establish standardized testing protocols. If confirmed by prospective studies, anti-MCV could be used to identify high-risk individuals and guide the timing of HRCT screening, optimizing resource utilization.

From a mechanistic perspective, vimentin is expressed in alveolar epithelial and interstitial cells, and environmental factors such as smoking can induce its citrullination, triggering ACPA responses, supporting the "lung-joint axis" hypothesis. Therefore, anti-MCV is not only a serum biomarker but may also reflect lung-initiated autoimmune processes. This provides a new perspective for exploring the origins of RA and suggests that the lung microenvironment may be a key target for early intervention in RA.

 

 

Conclusion

This review emphasizes the potential value of anti-MCV antibodies in the management of RA-ILD. Although current evidence is limited to only two small studies, the consistent finding of elevated anti-MCV in patients with pulmonary involvement and its association with pulmonary functional impairment suggests its feasibility as a non-invasive biomarker. Future multicenter, prospective cohort studies using standardized detection methods are needed to validate its diagnostic and prognostic value. If confirmed, anti-MCV could be integrated into existing screening pathways to assist in identifying high-risk RA patients who require early imaging monitoring, enabling earlier diagnosis and treatment. Furthermore, its specific binding to vimentin provides a molecular tool for exploring the pulmonary origin mechanisms of RA, promoting a shift from a "joint-centric" to a "systemic immune dysregulation" disease model. Ultimately, this will help build a more precise RA care system and improve patient outcomes.

 

Christian D’Elia, Giada Santagata, Serena Guiducci, Maria Infantino, and Maurizio Benucci. The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review. Antibodies.